{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:01:04Z","timestamp":1792735264199,"version":"4.5.0"},"reference-count":232,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"DOI":"10.1038\/s41584-022-00900-6","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T19:05:00Z","timestamp":1675710300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-4453","authenticated-orcid":false,"given":"Zsuzsanna H.","family":"McMahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9425-3209","authenticated-orcid":false,"given":"Joan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiande Z.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-5167","authenticated-orcid":false,"given":"Ramnik J.","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Jay","family":"Pasricha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"900_CR1","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","volume":"43","author":"VD Steen","year":"2000","unstructured":"Steen, V. D. & Medsger, T. A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 43, 2437\u20132444 (2000).","journal-title":"Arthritis Rheum."},{"key":"900_CR2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/key350","volume":"58","author":"N Richard","year":"2019","unstructured":"Richard, N. et al. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. Rheumatology 58, 636\u2013644 (2019).","journal-title":"Rheumatology"},{"key":"900_CR3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.rdc.2015.04.007","volume":"41","author":"G Gyger","year":"2015","unstructured":"Gyger, G. & Baron, M. Systemic sclerosis: gastrointestinal disease and its management. Rheum. Dis. Clin. North. Am. 41, 459\u2013473 (2015).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"900_CR4","doi-asserted-by":"crossref","first-page":"101666","DOI":"10.1016\/j.berh.2021.101666","volume":"35","author":"T Kaniecki","year":"2021","unstructured":"Kaniecki, T., Abdi, T. & McMahan, Z. H. A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis. Best Pract. Res. Clin. Rheumatol. 35, 101666 (2021).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"900_CR5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2004.08.009","volume":"34","author":"K Jaovisidha","year":"2005","unstructured":"Jaovisidha, K., Csuka, M. E., Almagro, U. A. & Soergel, K. H. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin. Arthritis Rheum. 34, 689\u2013702 (2005).","journal-title":"Semin. Arthritis Rheum."},{"key":"900_CR6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/acr.24488","volume":"74","author":"ZH McMahan","year":"2022","unstructured":"McMahan, Z. H. et al. Relationship between gastrointestinal transit, Medsger gastrointestinal severity, and University of California-Los Angeles scleroderma clinical trial consortium gastrointestinal tract 2.0 symptoms in patients with systemic sclerosis. Arthritis Care Res. 74, 442\u2013450 (2022).","journal-title":"Arthritis Care Res."},{"key":"900_CR7","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ard.2008.096545","volume":"68","author":"Y Kawaguchi","year":"2009","unstructured":"Kawaguchi, Y. et al. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility. Ann. Rheum. Dis. 68, 710\u2013714 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"900_CR8","first-page":"1330","volume":"25","author":"G Lock","year":"1998","unstructured":"Lock, G. et al. Association of autonomic nervous dysfunction and esophageal dysmotility in systemic sclerosis. J. Rheumatol. 25, 1330\u20131335 (1998).","journal-title":"J. Rheumatol."},{"key":"900_CR9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3899\/jrheum.170868","volume":"45","author":"BL Adler","year":"2018","unstructured":"Adler, B. L., Russell, J. W., Hummers, L. K. & McMahan, Z. H. Symptoms of autonomic dysfunction in systemic sclerosis assessed by the COMPASS-31 questionnaire. J. Rheumatol. 45, 1145\u20131152 (2018).","journal-title":"J. Rheumatol."},{"key":"900_CR10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-4939-0897-4_3","volume":"817","author":"JB Furness","year":"2014","unstructured":"Furness, J. B., Callaghan, B. P., Rivera, L. R. & Cho, H. J. The enteric nervous system and gastrointestinal innervation: integrated local and central control. Adv. Exp. Med. Biol. 817, 39\u201371 (2014).","journal-title":"Adv. Exp. Med. Biol."},{"key":"900_CR11","first-page":"E3709","volume":"114","author":"S Kulkarni","year":"2017","unstructured":"Kulkarni, S. et al. Adult enteric nervous system in health is maintained by a dynamic balance between neuronal apoptosis and neurogenesis. Proc. Natl Acad. Sci. USA 114, E3709\u2013E3718 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"900_CR12","doi-asserted-by":"crossref","first-page":"9346","DOI":"10.1523\/JNEUROSCI.1663-18.2018","volume":"38","author":"S Kulkarni","year":"2018","unstructured":"Kulkarni, S. et al. Advances in enteric neurobiology: the \u201cbrain\u201d in the gut in health and disease. J. Neurosci. 38, 9346\u20139354 (2018).","journal-title":"J. Neurosci."},{"key":"900_CR13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/j.gastro.2020.12.018","volume":"160","author":"S Kulkarni","year":"2021","unstructured":"Kulkarni, S. & Pasricha, P. J. Decoding the enteric nervous system: the beginning of our understanding of enteric neuromuscular disorders. Gastroenterology 160, 651\u2013652 (2021).","journal-title":"Gastroenterology"},{"key":"900_CR14","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/acr.23763","volume":"71","author":"ZH McMahan","year":"2019","unstructured":"McMahan, Z. H. et al. Anti-RNPC-3 (U11\/U12) antibodies in systemic sclerosis in patients with moderate-to-severe gastrointestinal dysmotility. Arthritis Care Res. 71, 1164\u20131170 (2019).","journal-title":"Arthritis Care Res."},{"key":"900_CR15","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/acr.23479","volume":"70","author":"ZH McMahan","year":"2018","unstructured":"McMahan, Z. H., Paik, J. J., Wigley, F. M. & Hummers, L. K. Determining the risk factors and clinical features associated with severe gastrointestinal dysmotility in systemic sclerosis. Arthritis Care Res. 70, 1385\u20131392 (2018).","journal-title":"Arthritis Care Res."},{"key":"900_CR16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.semarthrit.2019.05.005","volume":"49","author":"E Dein","year":"2019","unstructured":"Dein, E. et al. Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. Semin. Arthritis Rheum. 49, 405\u2013410 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"900_CR17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2967\/jnumed.120.243527","volume":"62","author":"HA Ziessman","year":"2021","unstructured":"Ziessman, H. A., Jeyasingam, M., Khan, A. U., McMahan, Z. & Pasricha, P. J. Experience with esophagogastrointestinal transit scintigraphy in the initial 229 patients: multiple regions of dysmotility are common. J. Nucl. Med. 62, 115\u2013122 (2021).","journal-title":"J. Nucl. Med."},{"key":"900_CR18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13075-017-1340-y","volume":"19","author":"B Vigone","year":"2017","unstructured":"Vigone, B. et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res. Ther. 19, 145 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"900_CR19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13075-016-1094-y","volume":"18","author":"GP Karamanolis","year":"2016","unstructured":"Karamanolis, G. P. et al. The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. Arthritis Res. Ther. 18, 195 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"900_CR20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11938-020-00314-x","volume":"18","author":"ZH McMahan","year":"2020","unstructured":"McMahan, Z. H. & Khanna, D. Managing gastrointestinal complications in patients with systemic sclerosis. Curr. Treat. Options Gastroenterol. 18, 531\u2013544 (2020).","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"900_CR21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/gut.2005.075002","volume":"55","author":"C Rigamonti","year":"2006","unstructured":"Rigamonti, C. et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 55, 388\u2013394 (2006).","journal-title":"Gut"},{"key":"900_CR22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13075-022-02790-1","volume":"24","author":"K Morrisroe","year":"2022","unstructured":"Morrisroe, K. et al. Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival. Arthritis Res. Ther. 24, 103 (2022).","journal-title":"Arthritis Res. Ther."},{"key":"900_CR23","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.cell.2020.08.003","volume":"182","author":"E Drokhlyansky","year":"2020","unstructured":"Drokhlyansky, E. et al. The human and mouse enteric nervous system at single-cell resolution. Cell 182, 1606\u20131622.e1623 (2020).","journal-title":"Cell"},{"key":"900_CR24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41593-020-00736-x","volume":"24","author":"K Morarach","year":"2021","unstructured":"Morarach, K. et al. Diversification of molecularly defined myenteric neuron classes revealed by single-cell RNA sequencing. Nat. Neurosci. 24, 34\u201346 (2021).","journal-title":"Nat. Neurosci."},{"key":"900_CR25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2020.02.004","volume":"180","author":"A Jarret","year":"2020","unstructured":"Jarret, A. et al. Enteric nervous system-derived IL-18 orchestrates mucosal barrier immunity. Cell 180, 813\u2013814 (2020).","journal-title":"Cell"},{"key":"900_CR26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.cell.2014.04.050","volume":"158","author":"PA Muller","year":"2014","unstructured":"Muller, P. A. et al. Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell 158, 300\u2013313 (2014).","journal-title":"Cell"},{"key":"900_CR27","doi-asserted-by":"crossref","first-page":"C1074","DOI":"10.1152\/ajpcell.00536.2020","volume":"320","author":"AJ Nickerson","year":"2021","unstructured":"Nickerson, A. J., Rottgen, T. S. & Rajendran, V. M. Activation of KCNQ (KV7) K+ channels in enteric neurons inhibits epithelial Cl\u2013 secretion in mouse distal colon. Am. J. Physiol. Cell Physiol. 320, C1074\u2013C1087 (2021).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"900_CR28","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1111\/bph.13555","volume":"173","author":"S Moreno","year":"2016","unstructured":"Moreno, S. et al. Epithelial propionyl- and butyrylcholine as novel regulators of colonic ion transport. Br. J. Pharmacol. 173, 2766\u20132779 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"900_CR29","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1007\/s00018-020-03543-6","volume":"77","author":"C Fung","year":"2020","unstructured":"Fung, C. & Vanden Berghe, P. Functional circuits and signal processing in the enteric nervous system. Cell Mol. Life Sci. 77, 4505\u20134522 (2020).","journal-title":"Cell Mol. Life Sci."},{"key":"900_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autneu.2007.04.005","volume":"136","author":"RJ Phillips","year":"2007","unstructured":"Phillips, R. J. & Powley, T. L. Innervation of the gastrointestinal tract: patterns of aging. Auton. Neurosci. 136, 1\u201319 (2007).","journal-title":"Auton. Neurosci."},{"key":"900_CR31","doi-asserted-by":"crossref","first-page":"dev182543","DOI":"10.1242\/dev.182543","volume":"148","author":"YN Kang","year":"2021","unstructured":"Kang, Y. N., Fung, C. & Vanden Berghe, P. Gut innervation and enteric nervous system development: a spatial, temporal and molecular tour de force. Development 148, dev182543 (2021).","journal-title":"Development"},{"key":"900_CR32","doi-asserted-by":"crossref","first-page":"700129","DOI":"10.3389\/fphys.2021.700129","volume":"12","author":"H Duan","year":"2021","unstructured":"Duan, H. et al. Regulation of the autonomic nervous system on intestine. Front. Physiol. 12, 700129 (2021).","journal-title":"Front. Physiol."},{"key":"900_CR33","doi-asserted-by":"crossref","first-page":"G576","DOI":"10.1152\/ajpgi.00214.2021","volume":"321","author":"TL Powley","year":"2021","unstructured":"Powley, T. L. Brain-gut communication: vagovagal reflexes interconnect the two \u201cbrains\u201d. Am. J. Physiol. Gastrointest. Liver Physiol. 321, G576\u2013G587 (2021).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"900_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ar.25015","author":"PM Masliukov","year":"2022","unstructured":"Masliukov, P. M., Emanuilov, A. I. & Budnik, A. F. Sympathetic innervation of the development, maturity, and aging of the gastrointestinal tract. Anat. Rec. https:\/\/doi.org\/10.1002\/ar.25015 (2022).","journal-title":"Anat. Rec."},{"key":"900_CR35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41575-021-00561-y","volume":"19","author":"A Mercado-Perez","year":"2022","unstructured":"Mercado-Perez, A. & Beyder, A. Gut feelings: mechanosensing in the gastrointestinal tract. Nat. Rev. Gastroenterol. Hepatol. 19, 283\u2013296 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"900_CR36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41575-020-0271-2","volume":"17","author":"NJ Spencer","year":"2020","unstructured":"Spencer, N. J. & Hu, H. Enteric nervous system: sensory transduction, neural circuits and gastrointestinal motility. Nat. Rev. Gastroenterol. Hepatol. 17, 338\u2013351 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"900_CR37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coi.2020.09.007","volume":"68","author":"S Kulkarni","year":"2021","unstructured":"Kulkarni, S., Kurapati, S. & Bogunovic, M. Neuro-innate immune interactions in gut mucosal immunity. Curr. Opin. Immunol. 68, 64\u201371 (2021).","journal-title":"Curr. Opin. Immunol."},{"key":"900_CR38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jaci.2022.07.015","volume":"150","author":"LR Dowling","year":"2022","unstructured":"Dowling, L. R., Strazzari, M. R., Keely, S. & Kaiko, G. E. Enteric nervous system and intestinal epithelial regulation of the gut-brain axis. J. Allergy Clin. Immunol. 150, 513\u2013522 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"900_CR39","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41575-022-00669-9","volume":"19","author":"N Vaes","year":"2022","unstructured":"Vaes, N., Idris, M., Boesmans, W., Alves, M. M. & Melotte, V. Nerves in gastrointestinal cancer: from mechanism to modulations. Nat. Rev. Gastroenterol. Hepatol. 19, 768\u2013784 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"900_CR40","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1007\/s00018-021-03812-y","volume":"78","author":"AM Holland","year":"2021","unstructured":"Holland, A. M., Bon-Frauches, A. C., Keszthelyi, D., Melotte, V. & Boesmans, W. The enteric nervous system in gastrointestinal disease etiology. Cell Mol. Life Sci. 78, 4713\u20134733 (2021).","journal-title":"Cell Mol. Life Sci."},{"key":"900_CR41","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1126\/science.abi6087","volume":"374","author":"G Agirman","year":"2021","unstructured":"Agirman, G., Yu, K. B. & Hsiao, E. Y. Signaling inflammation across the gut-brain axis. Science 374, 1087\u20131092 (2021).","journal-title":"Science"},{"key":"900_CR42","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41586-022-04515-5","volume":"603","author":"Q Zhao","year":"2022","unstructured":"Zhao, Q. et al. A multidimensional coding architecture of the vagal interoceptive system. Nature 603, 878\u2013884 (2022).","journal-title":"Nature"},{"key":"900_CR43","doi-asserted-by":"crossref","first-page":"100056","DOI":"10.1016\/j.ynpai.2020.100056","volume":"9","author":"VN Lagomarsino","year":"2021","unstructured":"Lagomarsino, V. N., Kostic, A. D. & Chiu, I. M. Mechanisms of microbial-neuronal interactions in pain and nociception. Neurobiol. Pain. 9, 100056 (2021).","journal-title":"Neurobiol. Pain."},{"key":"900_CR44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cell.2019.11.014","volume":"180","author":"NY Lai","year":"2020","unstructured":"Lai, N. Y. et al. Gut-innervating nociceptor neurons regulate Peyer\u2019s patch microfold cells and SFB levels to mediate Salmonella host defense. Cell 180, 33\u201349 e22 (2020).","journal-title":"Cell"},{"key":"900_CR45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/joim.12591","volume":"282","author":"NY Lai","year":"2017","unstructured":"Lai, N. Y., Mills, K. & Chiu, I. M. Sensory neuron regulation of gastrointestinal inflammation and bacterial host defence. J. Intern. Med. 282, 5\u201323 (2017).","journal-title":"J. Intern. Med."},{"key":"900_CR46","doi-asserted-by":"crossref","first-page":"G357","DOI":"10.1152\/ajpgi.00478.2002","volume":"284","author":"HY Chang","year":"2003","unstructured":"Chang, H. Y., Mashimo, H. & Goyal, R. K. IV Current concepts of vagal efferent projections to the gut. Am. J. Physiol. Gastrointest. Liver Physiol. 284, G357\u2013G366 (2003).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"900_CR47","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(95)91799-3","volume":"346","author":"KE Matzel","year":"1995","unstructured":"Matzel, K. E., Stadelmaier, U., Hohenfellner, M. & Gall, F. P. Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence. Lancet 346, 1124\u20131127 (1995).","journal-title":"Lancet"},{"key":"900_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10020-018-0068-8","volume":"25","author":"RA Willemze","year":"2019","unstructured":"Willemze, R. A. et al. Loss of intestinal sympathetic innervation elicits an innate immune driven colitis. Mol. Med. 25, 1 (2019).","journal-title":"Mol. Med."},{"key":"900_CR49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41586-020-2474-7","volume":"583","author":"PA Muller","year":"2020","unstructured":"Muller, P. A. et al. Microbiota modulate sympathetic neurons via a gut\u2013brain circuit. Nature 583, 441\u2013446 (2020).","journal-title":"Nature"},{"key":"900_CR50","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.cell.2016.10.020","volume":"167","author":"M Schirmer","year":"2016","unstructured":"Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1125\u20131136.e1128 (2016).","journal-title":"Cell"},{"key":"900_CR51","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-021-03832-5","volume":"599","author":"Y Sato","year":"2021","unstructured":"Sato, Y. et al. Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nature 599, 458\u2013464 (2021).","journal-title":"Nature"},{"key":"900_CR52","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/art.1780370902","volume":"37","author":"RW Sjogren","year":"1994","unstructured":"Sjogren, R. W. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 37, 1265\u20131282 (1994).","journal-title":"Arthritis Rheum."},{"key":"900_CR53","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/gut.2005.086074","volume":"55","author":"CG Roberts","year":"2006","unstructured":"Roberts, C. G., Hummers, L. K., Ravich, W. J., Wigley, F. M. & Hutchins, G. M. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 55, 1697\u20131703 (2006).","journal-title":"Gut"},{"key":"900_CR54","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0002-9343(69)90044-8","volume":"46","author":"WA D\u2019Angelo","year":"1969","unstructured":"D\u2019Angelo, W. A., Fries, J. F., Masi, A. T. & Shulman, L. E. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am. J. Med. 46, 428\u2013440 (1969).","journal-title":"Am. J. Med."},{"key":"900_CR55","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1172\/JCI117395","volume":"94","author":"S Howe","year":"1994","unstructured":"Howe, S. et al. Antimyenteric neuronal antibodies in scleroderma. J. Clin. Invest. 94, 761\u2013770 (1994).","journal-title":"J. Clin. Invest."},{"key":"900_CR56","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1053\/j.gastro.2012.07.109","volume":"143","author":"J Singh","year":"2012","unstructured":"Singh, J. et al. Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function. Gastroenterology 143, 1308\u20131318 (2012).","journal-title":"Gastroenterology"},{"key":"900_CR57","doi-asserted-by":"crossref","first-page":"G1206","DOI":"10.1152\/ajpgi.00286.2009","volume":"297","author":"J Singh","year":"2009","unstructured":"Singh, J. et al. Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G1206\u2013G1213 (2009).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"900_CR58","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.semarthrit.2013.05.002","volume":"43","author":"TN Amaral","year":"2013","unstructured":"Amaral, T. N., Peres, F. A., Lapa, A. T., Marques-Neto, J. F. & Appenzeller, S. Neurologic involvement in scleroderma: a systematic review. Semin. Arthritis Rheum. 43, 335\u2013347 (2013).","journal-title":"Semin. Arthritis Rheum."},{"key":"900_CR59","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/rheumatology\/ker153","volume":"50","author":"NM Thoua","year":"2011","unstructured":"Thoua, N. M., Schizas, A., Forbes, A., Denton, C. P. & Emmanuel, A. V. Internal anal sphincter atrophy in patients with systemic sclerosis. Rheumatology 50, 1596\u20131602 (2011).","journal-title":"Rheumatology"},{"key":"900_CR60","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/ajg.2011.399","volume":"107","author":"NM Thoua","year":"2012","unstructured":"Thoua, N. M., Abdel-Halim, M., Forbes, A., Denton, C. P. & Emmanuel, A. V. Fecal incontinence in systemic sclerosis is secondary to neuropathy. Am. J. Gastroenterol. 107, 597\u2013603 (2012).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR61","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-021-00853-7","volume":"13","author":"DR Plichta","year":"2021","unstructured":"Plichta, D. R. et al. Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis. Genome Med. 13, 35 (2021).","journal-title":"Genome Med."},{"key":"900_CR62","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.14309\/ajg.0000000000000260","volume":"114","author":"PT Kr\u00f6ner","year":"2019","unstructured":"Kr\u00f6ner, P. T., Tolaymat, O. A., Bowman, A. W., Abril, A. & Lacy, B. E. Gastrointestinal manifestations of rheumatological diseases. Am. J. Gastroenterol. 114, 1441\u20131454 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR63","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.18103\/mra.v8i10.2252","volume":"8","author":"T Kaniecki","year":"2020","unstructured":"Kaniecki, T., Abdi, T. & McMahan, Z. H. Clinical assessment of gastrointestinal involvement in patients with systemic sclerosis. Med. Res. Arch. 8, 2252 (2020).","journal-title":"Med. Res. Arch."},{"key":"900_CR64","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/apt.13963","volume":"45","author":"S Kumar","year":"2017","unstructured":"Kumar, S. et al. Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. Aliment. Pharmacol. Ther. 45, 883\u2013898 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"900_CR65","first-page":"235","volume":"8","author":"IM McFarlane","year":"2018","unstructured":"McFarlane, I. M. et al. Gastrointestinal manifestations of systemic sclerosis. Rheumatology (Sunnyvale) 8, 235 (2018).","journal-title":"Rheumatology (Sunnyvale)"},{"key":"900_CR66","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5455\/medarh.2015.69.153-156","volume":"69","author":"IH Bajraktari","year":"2015","unstructured":"Bajraktari, I. H. et al. Oral manifestations of systemic sclerosis and correlation with anti-topoisomerase I antibodies (SCL-70). Med. Arch. 69, 153\u2013156 (2015).","journal-title":"Med. Arch."},{"key":"900_CR67","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/odi.12507","volume":"23","author":"S Jung","year":"2017","unstructured":"Jung, S., Martin, T., Schmittbuhl, M. & Huck, O. The spectrum of orofacial manifestations in systemic sclerosis: a challenging management. Oral. Dis. 23, 424\u2013439 (2017).","journal-title":"Oral. Dis."},{"key":"900_CR68","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/ijms17071189","volume":"17","author":"V Crincoli","year":"2016","unstructured":"Crincoli, V. et al. Orofacial manifestations and temporomandibular disorders of systemic scleroderma: an observational study. Int. J. Mol. Sci. 17, 1189 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"900_CR69","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00784-010-0472-0","volume":"15","author":"CH Chu","year":"2011","unstructured":"Chu, C. H., Yeung, C. M., Lai, I. A., Leung, W. K. & Mok, M. Y. Oral health of Chinese people with systemic sclerosis. Clin. Oral. Investig. 15, 931\u2013939 (2011).","journal-title":"Clin. Oral. Investig."},{"key":"900_CR70","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.oooo.2015.03.002","volume":"120","author":"M Dagenais","year":"2015","unstructured":"Dagenais, M. et al. The Canadian Systemic Sclerosis Oral Health Study IV: oral radiographic manifestations in systemic sclerosis compared with the general population. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. 120, 104\u2013111 (2015).","journal-title":"Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol."},{"key":"900_CR71","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1259\/dmfr\/14556986","volume":"34","author":"A Auluck","year":"2005","unstructured":"Auluck, A., Pai, K. M., Shetty, C. & Shenoi, S. D. Mandibular resorption in progressive systemic sclerosis: a report of three cases. Dentomaxillofac Radiol. 34, 384\u2013386 (2005).","journal-title":"Dentomaxillofac Radiol."},{"key":"900_CR72","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/jop.13177","volume":"50","author":"I Abdouh","year":"2021","unstructured":"Abdouh, I. et al. Measuring the impact of systemic sclerosis on oral health-related quality of life in a UK population. J. Oral. Pathol. Med. 50, 812\u2013819 (2021).","journal-title":"J. Oral. Pathol. Med."},{"key":"900_CR73","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/rheumatology\/ket441","volume":"53","author":"M Baron","year":"2014","unstructured":"Baron, M. et al. The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. Rheumatology 53, 1386\u20131394 (2014).","journal-title":"Rheumatology"},{"key":"900_CR74","first-page":"115","volume":"34","author":"J Raja","year":"2016","unstructured":"Raja, J., Ng, C. T., Sujau, I., Chin, K. F. & Sockalingam, S. High-resolution oesophageal manometry and 24-hour impedance-pH study in systemic sclerosis patients: association with clinical features, symptoms and severity. Clin. Exp. Rheumatol. 34, 115\u2013121 (2016).","journal-title":"Clin. Exp. Rheumatol."},{"key":"900_CR75","first-page":"763","volume":"92","author":"G Lock","year":"1997","unstructured":"Lock, G., Holstege, A., Lang, B. & Scholmerich, J. Gastrointestinal manifestations of progressive systemic sclerosis. Am. J. Gastroenterol. 92, 763\u2013771 (1997).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR76","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1572-0241.1998.00341.x","volume":"93","author":"G Lock","year":"1998","unstructured":"Lock, G. et al. Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am. J. Gastroenterol. 93, 341\u2013345 (1998).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR77","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/j.1572-0241.1998.00334.x","volume":"93","author":"S Weston","year":"1998","unstructured":"Weston, S., Thumshirn, M., Wiste, J. & Camilleri, M. Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am. J. Gastroenterol. 93, 1085\u20131089 (1998).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR78","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1442-2050.1999.00005.x","volume":"12","author":"MA Henry","year":"1999","unstructured":"Henry, M. A., Harbermann, M. C. & Rocha, O. M. Esophageal motor disturbances in progressive systemic sclerosis. Dis. Esophagus 12, 51\u201353 (1999).","journal-title":"Dis. Esophagus"},{"key":"900_CR79","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12876-015-0241-2","volume":"15","author":"T Arif","year":"2015","unstructured":"Arif, T., Masood, Q., Singh, J. & Hassan, I. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. BMC Gastroenterol. 15, 24 (2015).","journal-title":"BMC Gastroenterol."},{"key":"900_CR80","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/nmo.12477","volume":"27","author":"PJ Kahrilas","year":"2015","unstructured":"Kahrilas, P. J. et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol. Motil. 27, 160\u2013174 (2015).","journal-title":"Neurogastroenterol. Motil."},{"key":"900_CR81","volume":"33","author":"R Yadlapati","year":"2021","unstructured":"Yadlapati, R. et al. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0. Neurogastroenterol. Motil. 33, e14058 (2021).","journal-title":"Neurogastroenterol. Motil."},{"key":"900_CR82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dox067","volume":"30","author":"N Aggarwal","year":"2017","unstructured":"Aggarwal, N. et al. Spectrum of esophageal dysmotility in systemic sclerosis on high-resolution esophageal manometry as defined by Chicago classification. Dis. Esophagus 30, 1\u20136 (2017).","journal-title":"Dis. Esophagus"},{"key":"900_CR83","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1442-2050.2010.01150.x","volume":"24","author":"S Roman","year":"2011","unstructured":"Roman, S. et al. Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study. Dis. Esophagus 24, 299\u2013304 (2011).","journal-title":"Dis. Esophagus"},{"key":"900_CR84","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1093\/rheumatology\/keac074","volume":"61","author":"B Adler","year":"2022","unstructured":"Adler, B., Hummers, L. K., Pasricha, P. J. & McMahan, Z. H. Gastroparesis in systemic sclerosis: a detailed analysis using whole-gut scintigraphy. Rheumatology 61, 4503\u20134508 (2022).","journal-title":"Rheumatology"},{"key":"900_CR85","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/BF02090373","volume":"39","author":"M Wegener","year":"1994","unstructured":"Wegener, M., Adamek, R. J., Wedmann, B., Jergas, M. & Altmeyer, P. Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig. Dis. Sci. 39, 2209\u20132215 (1994).","journal-title":"Dig. Dis. Sci."},{"key":"900_CR86","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s10067-018-4026-1","volume":"37","author":"S Vettori","year":"2018","unstructured":"Vettori, S. et al. Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value. Clin. Rheumatol. 37, 1239\u20131247 (2018).","journal-title":"Clin. Rheumatol."},{"key":"900_CR87","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.gtc.2021.08.005","volume":"50","author":"NK Ahuja","year":"2021","unstructured":"Ahuja, N. K. & Clarke, J. O. Scleroderma and the esophagus. Gastroenterol. Clin. North. Am. 50, 905\u2013918 (2021).","journal-title":"Gastroenterol. Clin. North. Am."},{"key":"900_CR88","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.semarthrit.2010.03.002","volume":"40","author":"RB Christmann","year":"2010","unstructured":"Christmann, R. B., Wells, A. U., Capelozzi, V. L. & Silver, R. M. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin. Arthritis Rheum. 40, 241\u2013249 (2010).","journal-title":"Semin. Arthritis Rheum."},{"key":"900_CR89","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0003-4975(10)63972-0","volume":"22","author":"MB Orringer","year":"1976","unstructured":"Orringer, M. B., Dabich, L., Zarafonetis, C. J. & Sloan, H. Gastroesophageal reflux in esophageal scleroderma: diagnosis and implications. Ann. Thorac. Surg. 22, 120\u2013130 (1976).","journal-title":"Ann. Thorac. Surg."},{"key":"900_CR90","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0002-9343(87)90376-7","volume":"82","author":"DA Katzka","year":"1987","unstructured":"Katzka, D. A. et al. Barrett\u2019s metaplasia and adenocarcinoma of the esophagus in scleroderma. Am. J. Med. 82, 46\u201352 (1987).","journal-title":"Am. J. Med."},{"key":"900_CR91","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/gastro\/goaa096","volume":"9","author":"M Anilkumar","year":"2021","unstructured":"Anilkumar, M., Alkhayyat, M., Grewal, U. S., Sanaka, M. R. & Thota, P. N. Higher risk of neoplastic progression of Barrett\u2019s esophagus in patients with systemic sclerosis. Gastroenterol. Rep. 9, 595\u2013596 (2021).","journal-title":"Gastroenterol. Rep."},{"key":"900_CR92","doi-asserted-by":"crossref","first-page":"517","DOI":"10.14309\/ajg.0000000000001109","volume":"116","author":"DL Snyder","year":"2021","unstructured":"Snyder, D. L. et al. Prevalence of Barrett\u2019s esophagus in female patients with scleroderma. Am. J. Gastroenterol. 116, 517\u2013521 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR93","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1136\/gutjnl-2014-307595","volume":"64","author":"RH Hunt","year":"2015","unstructured":"Hunt, R. H. et al. The stomach in health and disease. Gut 64, 1650\u20131668 (2015).","journal-title":"Gut"},{"key":"900_CR94","first-page":"1324","volume":"88","author":"JD Chen","year":"1993","unstructured":"Chen, J. D. & McCallum, R. W. Clinical applications of electrogastrography. Am. J. Gastroenterol. 88, 1324\u20131336 (1993).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR95","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/rheumatology\/kes429","volume":"52","author":"E Savarino","year":"2013","unstructured":"Savarino, E. et al. Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology 52, 1095\u20131100 (2013).","journal-title":"Rheumatology"},{"key":"900_CR96","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.semarthrit.2012.09.004","volume":"42","author":"L Gemignani","year":"2013","unstructured":"Gemignani, L. et al. Lactulose breath test to assess oro-cecal transit delay and estimate esophageal dysmotility in scleroderma patients. Semin. Arthritis Rheum. 42, 522\u2013529 (2013).","journal-title":"Semin. Arthritis Rheum."},{"key":"900_CR97","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1002\/art.34374","volume":"64","author":"I Marie","year":"2012","unstructured":"Marie, I. et al. Delayed gastric emptying determined using the 13C-octanoic acid breath test in patients with systemic sclerosis. Arthritis Rheum. 64, 2346\u20132355 (2012).","journal-title":"Arthritis Rheum."},{"key":"900_CR98","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/03009740410005016","volume":"32","author":"K Franck-Larsson","year":"2003","unstructured":"Franck-Larsson, K., Hedenstr\u00f6m, H., Dahl, R. & R\u00f6nnblom, A. Delayed gastric emptying in patients with diffuse versus limited systemic sclerosis, unrelated to gastrointestinal symptoms and myoelectric gastric activity. Scand. J. Rheumatol. 32, 348\u2013355 (2003).","journal-title":"Scand. J. Rheumatol."},{"key":"900_CR99","first-page":"G90","volume":"266","author":"JD Chen","year":"1994","unstructured":"Chen, J. D., Schirmer, B. D. & McCallum, R. W. Serosal and cutaneous recordings of gastric myoelectrical activity in patients with gastroparesis. Am. J. Physiol. 266, G90\u2013G98 (1994).","journal-title":"Am. J. Physiol."},{"key":"900_CR100","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1023\/A:1014759109982","volume":"47","author":"T McNearney","year":"2002","unstructured":"McNearney, T., Lin, X., Shrestha, J., Lisse, J. & Chen, J. D. Characterization of gastric myoelectrical rhythms in patients with systemic sclerosis using multichannel surface electrogastrography. Dig. Dis. Sci. 47, 690\u2013698 (2002).","journal-title":"Dig. Dis. Sci."},{"key":"900_CR101","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1365-2982.2009.01350.x","volume":"21","author":"TA McNearney","year":"2009","unstructured":"McNearney, T. A. et al. Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients. Neurogastroenterol. Motil. 21, 1269\u2013e1120 (2009).","journal-title":"Neurogastroenterol. Motil."},{"key":"900_CR102","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11938-000-0042-7","volume":"3","author":"J Tack","year":"2000","unstructured":"Tack, J. Functional dyspepsia: impaired fundic accommodation. Curr. Treat. Options Gastroenterol. 3, 287\u2013294 (2000).","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"900_CR103","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0022-2143(98)90133-0","volume":"132","author":"KR Sridhar","year":"1998","unstructured":"Sridhar, K. R., Lange, R. C., Magyar, L., Soykan, I. & McCallum, R. W. Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications. J. Lab. Clin. Med. 132, 541\u2013546 (1998).","journal-title":"J. Lab. Clin. Med."},{"key":"900_CR104","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3899\/jrheum.130386","volume":"41","author":"E Ghr\u00e9nassia","year":"2014","unstructured":"Ghr\u00e9nassia, E. et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J. Rheumatol. 41, 99\u2013105 (2014).","journal-title":"J. Rheumatol."},{"key":"900_CR105","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/rheumatology\/kes160","volume":"51","author":"E Harrison","year":"2012","unstructured":"Harrison, E., Herrick, A. L., McLaughlin, J. T. & Lal, S. Malnutrition in systemic sclerosis. Rheumatology 51, 1747\u20131756 (2012).","journal-title":"Rheumatology"},{"key":"900_CR106","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00296-003-0286-3","volume":"23","author":"L Caserta","year":"2003","unstructured":"Caserta, L. et al. Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters. Rheumatol. Int. 23, 226\u2013230 (2003).","journal-title":"Rheumatol. Int."},{"key":"900_CR107","first-page":"2159","volume":"26","author":"TA Medsger","year":"1999","unstructured":"Medsger, T. A. et al. A disease severity scale for systemic sclerosis: development and testing. J. Rheumatol. 26, 2159\u20132167 (1999).","journal-title":"J. Rheumatol."},{"key":"900_CR108","first-page":"512","volume":"100","author":"E Savarino","year":"2009","unstructured":"Savarino, E. et al. Possible connection between gastroesophageal reflux and interstitial pulmonary fibrosis in patients with systemic sclerosis. Recent. Prog. Med. 100, 512\u2013516 (2009).","journal-title":"Recent. Prog. Med."},{"key":"900_CR109","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/j.1572-0241.2007.01758.x","volume":"103","author":"A Parodi","year":"2008","unstructured":"Parodi, A. et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am. J. Gastroenterol. 103, 1257\u20131262 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR110","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/gut.2005.075127","volume":"55","author":"M Simr\u00e9n","year":"2006","unstructured":"Simr\u00e9n, M. & Stotzer, P. O. Use and abuse of hydrogen breath tests. Gut 55, 297\u2013303 (2006).","journal-title":"Gut"},{"key":"900_CR111","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/MOG.0000000000000040","volume":"30","author":"EM Quigley","year":"2014","unstructured":"Quigley, E. M. Small intestinal bacterial overgrowth: what it is and what it is not. Curr. Opin. Gastroenterol. 30, 141\u2013146 (2014).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"900_CR112","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/2040622313496126","volume":"4","author":"AH Sachdev","year":"2013","unstructured":"Sachdev, A. H. & Pimentel, M. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther. Adv. Chronic Dis. 4, 223\u2013231 (2013).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"900_CR113","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/rheumatology\/34.3.265","volume":"34","author":"SA Kaye","year":"1995","unstructured":"Kaye, S. A. et al. Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br. J. Rheumatol. 34, 265\u2013269 (1995).","journal-title":"Br. J. Rheumatol."},{"key":"900_CR114","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1007\/s10067-020-05549-8","volume":"40","author":"X Feng","year":"2021","unstructured":"Feng, X., Li, X. Q. & Jiang, Z. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis. Clin. Rheumatol. 40, 3039\u20133051 (2021).","journal-title":"Clin. Rheumatol."},{"key":"900_CR115","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/rheumatology\/kep226","volume":"48","author":"I Marie","year":"2009","unstructured":"Marie, I., Ducrott\u00e9, P., Denis, P., Menard, J. F. & Levesque, H. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology 48, 1314\u20131319 (2009).","journal-title":"Rheumatology"},{"key":"900_CR116","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.clnesp.2015.03.004","volume":"10","author":"E Harrison","year":"2015","unstructured":"Harrison, E., Herrick, A. L., McLaughlin, J. T. & Lal, S. An assessment of the nutritional status of patients with systemic sclerosis. Clin. Nutr. ESPEN 10, e177\u2013e178 (2015).","journal-title":"Clin. Nutr. ESPEN"},{"key":"900_CR117","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/rheumatology\/kev393","volume":"55","author":"A Valenzuela","year":"2016","unstructured":"Valenzuela, A. et al. Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the Nationwide Inpatient Sample. Rheumatology 55, 654\u2013658 (2016).","journal-title":"Rheumatology"},{"key":"900_CR118","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3899\/jrheum.131547","volume":"41","author":"C Mecoli","year":"2014","unstructured":"Mecoli, C., Purohit, S., Sandorfi, N. & Derk, C. T. Mortality, recurrence, and hospital course of patients with systemic sclerosis-related acute intestinal pseudo-obstruction. J. Rheumatol. 41, 2049\u20132054 (2014).","journal-title":"J. Rheumatol."},{"key":"900_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24767","author":"JX Cheah","year":"2021","unstructured":"Cheah, J. X. et al. Slow colonic transit in systemic sclerosis: an objective assessment of risk factors and clinical phenotype. Arthritis Care Res. https:\/\/doi.org\/10.1002\/acr.24767 (2021).","journal-title":"Arthritis Care Res."},{"key":"900_CR120","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF02586669","volume":"21","author":"K Nagasako","year":"1978","unstructured":"Nagasako, K., Ota, Y., Sasaki, H. & Hamano, K. Progressive systemic sclerosis: report of a case with colonic involvement. Dis. Colon. Rectum 21, 364\u2013368 (1978).","journal-title":"Dis. Colon. Rectum"},{"key":"900_CR121","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/003655299750026434","volume":"34","author":"M Trezza","year":"1999","unstructured":"Trezza, M., Krogh, K., Egekvist, H., Bjerring, P. & Laurberg, S. Bowel problems in patients with systemic sclerosis. Scand. J. Gastroenterol. 34, 409\u2013413 (1999).","journal-title":"Scand. J. Gastroenterol."},{"key":"900_CR122","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/MCG.0000000000000405","volume":"50","author":"SB Umar","year":"2016","unstructured":"Umar, S. B. et al. The impact of pelvic floor and lower gastrointestinal symptoms on quality of life in women with systemic sclerosis. J. Clin. Gastroenterol. 50, e55\u2013e59 (2016).","journal-title":"J. Clin. Gastroenterol."},{"key":"900_CR123","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/gut.35.6.857","volume":"35","author":"AF Engel","year":"1994","unstructured":"Engel, A. F., Kamm, M. A. & Talbot, I. C. Progressive systemic sclerosis of the internal anal sphincter leading to passive faecal incontinence. Gut 35, 857\u2013859 (1994).","journal-title":"Gut"},{"key":"900_CR124","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00004836-199710000-00006","volume":"25","author":"BW Jaffin","year":"1997","unstructured":"Jaffin, B. W., Chang, P. & Spiera, H. Fecal incontinence in scleroderma. Clinical features, anorectal manometric findings, and their therapeutic implications. J. Clin. Gastroenterol. 25, 513\u2013517 (1997).","journal-title":"J. Clin. Gastroenterol."},{"key":"900_CR125","first-page":"581","volume":"56","author":"N Richard","year":"2017","unstructured":"Richard, N. et al. Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. Rheumatology 56, 581\u2013588 (2017).","journal-title":"Rheumatology"},{"key":"900_CR126","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3109\/03009742.2011.579575","volume":"40","author":"L Fynne","year":"2011","unstructured":"Fynne, L., Wors\u00f8e, J., Laurberg, S. & Krogh, K. Faecal incontinence in patients with systemic sclerosis: is an impaired internal anal sphincter the only cause. Scand. J. Rheumatol. 40, 462\u2013466 (2011).","journal-title":"Scand. J. Rheumatol."},{"key":"900_CR127","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1111\/codi.12063","volume":"15","author":"L Fynne","year":"2013","unstructured":"Fynne, L. et al. Distensibility of the anal canal in patients with systemic sclerosis: a study with the functional lumen imaging probe. Colorectal Dis. 15, e40\u2013e47 (2013).","journal-title":"Colorectal Dis."},{"key":"900_CR128","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrgastro.2016.53","volume":"13","author":"SS Rao","year":"2016","unstructured":"Rao, S. S., Rattanakovit, K. & Patcharatrakul, T. Diagnosis and management of chronic constipation in adults. Nat. Rev. Gastroenterol. Hepatol. 13, 295\u2013305 (2016).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"900_CR129","doi-asserted-by":"crossref","first-page":"758","DOI":"10.14309\/ajg.0000000000001039","volume":"116","author":"PF Vollebregt","year":"2021","unstructured":"Vollebregt, P. F., Burgell, R. E., Hooper, R. L., Knowles, C. H. & Scott, S. M. Clinical impact of rectal hyposensitivity: a cross-sectional study of 2,876 patients with refractory functional constipation. Am. J. Gastroenterol. 116, 758\u2013768 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3346\/jkms.1996.11.3.244","volume":"11","author":"KC Kim","year":"1996","unstructured":"Kim, K. C. et al. Anorectal dysfunction in systemic sclerosis. J. Korean Med. Sci. 11, 244\u2013249 (1996).","journal-title":"J. Korean Med. Sci."},{"key":"900_CR131","doi-asserted-by":"crossref","first-page":"402583","DOI":"10.5402\/2011\/402583","volume":"2011","author":"HS Sallam","year":"2011","unstructured":"Sallam, H. S., McNearney, T. A. & Chen, J. Z. Anorectal motility and sensation abnormalities and its correlation with anorectal symptoms in patients with systemic sclerosis: a preliminary study. ISRN Gastroenterol. 2011, 402583 (2011).","journal-title":"ISRN Gastroenterol."},{"key":"900_CR132","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2967\/jnumed.114.152074","volume":"56","author":"AJ Antoniou","year":"2015","unstructured":"Antoniou, A. J. et al. Comprehensive radionuclide esophagogastrointestinal transit study: methodology, reference values, and initial clinical experience. J. Nucl. Med. 56, 721\u2013727 (2015).","journal-title":"J. Nucl. Med."},{"key":"900_CR133","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.semarthrit.2017.12.007","volume":"48","author":"NK Ahuja","year":"2018","unstructured":"Ahuja, N. K., Mische, L., Clarke, J. O., Wigley, F. M. & McMahan, Z. H. Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis. Semin. Arthritis Rheum. 48, 111\u2013116 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"900_CR134","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.1987.00370090075014","volume":"147","author":"DA Johnson","year":"1987","unstructured":"Johnson, D. A. et al. Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities. Arch. Intern. Med. 147, 1597\u20131601 (1987).","journal-title":"Arch. Intern. Med."},{"key":"900_CR135","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/j.cgh.2021.05.063","volume":"20","author":"I Sarosiek","year":"2022","unstructured":"Sarosiek, I. et al. Effect of domperidone therapy on gastroparesis symptoms: results of a dynamic cohort study by NIDDK gastroparesis consortium. Clin. Gastroenterol. Hepatol. 20, e452\u2013e464 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"900_CR136","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1111\/bcp.14737","volume":"87","author":"LB Ou","year":"2021","unstructured":"Ou, L. B., Moriello, C., Douros, A. & Filion, K. B. Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: a systematic review and meta-analysis of observational studies. Br. J. Clin. Pharmacol. 87, 3649\u20133658 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"900_CR137","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrgastro.2015.163","volume":"13","author":"GJ Sanger","year":"2016","unstructured":"Sanger, G. J. & Furness, J. B. Ghrelin and motilin receptors as drug targets for gastrointestinal disorders. Nat. Rev. Gastroenterol. Hepatol. 13, 38\u201348 (2016).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"900_CR138","first-page":"550","volume":"89","author":"S Fiorucci","year":"1994","unstructured":"Fiorucci, S., Distrutti, E., Gerli, R. & Morelli, A. Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. Am. J. Gastroenterol. 89, 550\u2013555 (1994).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR139","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1056\/NEJM199111213252102","volume":"325","author":"HC Soudah","year":"1991","unstructured":"Soudah, H. C., Hasler, W. L. & Owyang, C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N. Engl. J. Med. 325, 1461\u20131467 (1991).","journal-title":"N. Engl. J. Med."},{"key":"900_CR140","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000201407","volume":"57","author":"M Camilleri","year":"1996","unstructured":"Camilleri, M. Effects of somatostatin analogues on human gastrointestinal motility. Digestion 57, 90\u201392 (1996).","journal-title":"Digestion"},{"key":"900_CR141","first-page":"S-214","volume":"32","author":"N Hansi","year":"2014","unstructured":"Hansi, N. et al. Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clin. Exp. Rheumatol. 32, S-214\u2013S-221 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"900_CR142","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s40674-014-0005-0","volume":"1","author":"V Nagaraja","year":"2015","unstructured":"Nagaraja, V., McMahan, Z. H., Getzug, T. & Khanna, D. Management of gastrointestinal involvement in scleroderma. Curr. Treatm. Opt. Rheumatol. 1, 82\u2013105 (2015).","journal-title":"Curr. Treatm. Opt. Rheumatol."},{"key":"900_CR143","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1016\/S2665-9913(22)00183-7","volume":"4","author":"M Hughes","year":"2022","unstructured":"Hughes, M. et al. Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease. Lancet Rheumatol. 4, e795\u2013e803 (2022).","journal-title":"Lancet Rheumatol."},{"key":"900_CR144","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-57636-0","volume":"10","author":"C Foocharoen","year":"2020","unstructured":"Foocharoen, C. et al. Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study. Sci. Rep. 10, 769 (2020).","journal-title":"Sci. Rep."},{"key":"900_CR145","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cgh.2009.12.022","volume":"8","author":"L Lombardo","year":"2010","unstructured":"Lombardo, L., Foti, M., Ruggia, O. & Chiecchio, A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin. Gastroenterol. Hepatol. 8, 504\u2013508 (2010).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"900_CR146","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cgh.2022.01.025","volume":"20","author":"R Yadlapati","year":"2022","unstructured":"Yadlapati, R., Gyawali, C. P., Pandolfino, J. E. et al. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: expert review. Clin. Gastroenterol. Hepatol. 20, 984\u2013994.e981 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"900_CR147","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/gutjnl-2017-314722","volume":"67","author":"CP Gyawali","year":"2018","unstructured":"Gyawali, C. P. et al. Modern diagnosis of GERD: the Lyon Consensus. Gut 67, 1351\u20131362 (2018).","journal-title":"Gut"},{"key":"900_CR148","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/23971983211021747","volume":"7","author":"Y Shirai","year":"2022","unstructured":"Shirai, Y., Kawami, N., Iwakiri, K. & Kuwana, M. Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis. J. Scleroderma Relat. Disord. 7, 57\u201361 (2022).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"900_CR149","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11894-020-0753-y","volume":"22","author":"F Shibli","year":"2020","unstructured":"Shibli, F., Kitayama, Y. & Fass, R. Novel therapies for gastroesophageal reflux disease: beyond proton pump inhibitors. Curr. Gastroenterol. Rep. 22, 16 (2020).","journal-title":"Curr. Gastroenterol. Rep."},{"key":"900_CR150","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/rheumatology\/kew216","volume":"56","author":"C Foocharoen","year":"2017","unstructured":"Foocharoen, C. et al. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. Rheumatology 56, 214\u2013222 (2017).","journal-title":"Rheumatology"},{"key":"900_CR151","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1136\/gut.52.10.1397","volume":"52","author":"GH Koek","year":"2003","unstructured":"Koek, G. H., Sifrim, D., Lerut, T., Janssens, J. & Tack, J. Effect of the GABAB agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52, 1397\u20131402 (2003).","journal-title":"Gut"},{"key":"900_CR152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dow020","volume":"30","author":"DA Leiman","year":"2017","unstructured":"Leiman, D. A. et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis. Esophagus 30, 1\u20139 (2017).","journal-title":"Dis. Esophagus"},{"key":"900_CR153","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2147\/DDDT.S125743","volume":"11","author":"M Malamood","year":"2017","unstructured":"Malamood, M., Roberts, A., Kataria, R., Parkman, H. P. & Schey, R. Mirtazapine for symptom control in refractory gastroparesis. Drug. Des. Devel. Ther. 11, 1035\u20131041 (2017).","journal-title":"Drug. Des. Devel. Ther."},{"key":"900_CR154","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/jcpt.12851","volume":"44","author":"BB Jubran","year":"2019","unstructured":"Jubran, B. B., Bolduc, J., Eng, A., Stapleton, M. & Wilson, B. J. Off-label use of aprepitant for scleroderma-associated nausea and vomiting: a case report. J. Clin. Pharm. Ther. 44, 805\u2013808 (2019).","journal-title":"J. Clin. Pharm. Ther."},{"key":"900_CR155","doi-asserted-by":"crossref","first-page":"945","DOI":"10.14309\/ajg.0000000000000181","volume":"114","author":"A Jehangir","year":"2019","unstructured":"Jehangir, A. & Parkman, H. P. Cannabinoid use in patients with gastroparesis and related disorders: prevalence and benefit. Am. J. Gastroenterol. 114, 945\u2013953 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR156","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cgh.2012.06.036","volume":"10","author":"J Tack","year":"2012","unstructured":"Tack, J., Janssen, P., Masaoka, T., Farr\u00e9, R. & Van Oudenhove, L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin. Gastroenterol. Hepatol. 10, 1239\u20131245 (2012).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"900_CR157","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/rheumatology\/key175","volume":"57","author":"N Pittman","year":"2018","unstructured":"Pittman, N. et al. Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. Rheumatology 57, 1802\u20131811 (2018).","journal-title":"Rheumatology"},{"key":"900_CR158","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/gut.29.4.552","volume":"29","author":"P Pazzi","year":"1988","unstructured":"Pazzi, P., Putinati, S., Bagni, B., Govoni, M. & Trotta, F. Bile acid malabsorption in progressive systemic sclerosis. Gut 29, 552\u2013553 (1988).","journal-title":"Gut"},{"key":"900_CR159","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11894-018-0615-z","volume":"20","author":"P Vijayvargiya","year":"2018","unstructured":"Vijayvargiya, P. & Camilleri, M. Update on bile acid malabsorption: finally ready for prime time? Curr. Gastroenterol. Rep. 20, 10 (2018).","journal-title":"Curr. Gastroenterol. Rep."},{"key":"900_CR160","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/14656566.2014.900543","volume":"15","author":"M Corsetti","year":"2014","unstructured":"Corsetti, M. & Tack, J. New pharmacological treatment options for chronic constipation. Expert Opin. Pharmacother. 15, 927\u2013941 (2014).","journal-title":"Expert Opin. Pharmacother."},{"key":"900_CR161","first-page":"175628481877794","volume":"11","author":"SSC Rao","year":"2018","unstructured":"Rao, S. S. C. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. Ther. Adv. Gastroenterol. 11, 1756284818777945 (2018).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"900_CR162","volume":"31","author":"S Fukudo","year":"2019","unstructured":"Fukudo, S. et al. High-dose linaclotide is effective and safe in patients with chronic constipation: a phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan. Neurogastroenterol. Motil. 31, e13487 (2019).","journal-title":"Neurogastroenterol. Motil."},{"key":"900_CR163","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13492","volume":"31","author":"AD Farmer","year":"2019","unstructured":"Farmer, A. D., Ruffle, J. K. & Hobson, A. R. Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation. Neurogastroenterol. Motil. 31, e13492 (2019).","journal-title":"Neurogastroenterol. Motil."},{"key":"900_CR164","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1053\/j.gastro.2007.06.067","volume":"133","author":"V Andresen","year":"2007","unstructured":"Andresen, V. et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133, 761\u2013768 (2007).","journal-title":"Gastroenterology"},{"key":"900_CR165","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s10620-011-1801-0","volume":"56","author":"AJ Lembo","year":"2011","unstructured":"Lembo, A. J. et al. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig. Dis. Sci. 56, 2639\u20132645 (2011).","journal-title":"Dig. Dis. Sci."},{"key":"900_CR166","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","volume":"29","author":"DA Drossman","year":"2009","unstructured":"Drossman, D. A. et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome \u2014 results of two randomized, placebo-controlled studies. Aliment. Pharmacol. Ther. 29, 329\u2013341 (2009).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"900_CR167","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ajg.2016.611","volume":"112","author":"PB Miner","year":"2017","unstructured":"Miner, P. B. et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am. J. Gastroenterol. 112, 613\u2013621 (2017).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR168","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/17512433.2019.1670057","volume":"12","author":"G Bassotti","year":"2019","unstructured":"Bassotti, G., Usai Satta, P. & Bellini, M. Plecanatide for the treatment of chronic idiopathic constipation in adult patients. Expert. Rev. Clin. Pharmacol. 12, 1019\u20131026 (2019).","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"900_CR169","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12876-021-01738-0","volume":"21","author":"EJ Dein","year":"2021","unstructured":"Dein, E. J., Wigley, F. M. & McMahan, Z. H. Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis. BMC Gastroenterol. 21, 174 (2021).","journal-title":"BMC Gastroenterol"},{"key":"900_CR170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bpg.2011.01.004","volume":"25","author":"SS Rao","year":"2011","unstructured":"Rao, S. S. Biofeedback therapy for constipation in adults. Best. Pract. Res. Clin. Gastroenterol. 25, 159\u2013166 (2011).","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"900_CR171","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/codi.12969","volume":"17","author":"SK Butt","year":"2015","unstructured":"Butt, S. K. et al. Lack of effect of sacral nerve stimulation for incontinence in patients with systemic sclerosis. Colorectal Dis. 17, 903\u2013907 (2015).","journal-title":"Colorectal Dis."},{"key":"900_CR172","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1525-1403.2012.00429.x","volume":"15","author":"J Yin","year":"2012","unstructured":"Yin, J., Abell, T. D., McCallum, R. W. & Chen, J. D. Gastric neuromodulation with Enterra system for nausea and vomiting in patients with gastroparesis. Neuromodulation 15, 224\u2013231 (2012).","journal-title":"Neuromodulation"},{"key":"900_CR173","doi-asserted-by":"crossref","first-page":"G700","DOI":"10.1152\/ajpgi.00426.2020","volume":"320","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. Transcutaneous auricular vagal nerve stimulation improves functional dyspepsia by enhancing vagal efferent activity. Am. J. Physiol. Gastrointest. Liver Physiol. 320, G700\u2013G711 (2021).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"900_CR174","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13769","volume":"32","author":"A Gottfried-Blackmore","year":"2020","unstructured":"Gottfried-Blackmore, A. et al. Open-label pilot study: Non-invasive vagal nerve stimulation improves symptoms and gastric emptying in patients with idiopathic gastroparesis. Neurogastroenterol. Motil. 32, e13769 (2020).","journal-title":"Neurogastroenterol. Motil."},{"key":"900_CR175","volume":"30","author":"JDZ Chen","year":"2018","unstructured":"Chen, J. D. Z., Ni, M. & Yin, J. Electroacupuncture treatments for gut motility disorders. Neurogastroenterol. Motil. 30, e13393 (2018).","journal-title":"Neurogastroenterol. Motil."},{"key":"900_CR176","first-page":"140","volume":"31","author":"TA McNearney","year":"2013","unstructured":"McNearney, T. A., Sallam, H. S., Hunnicutt, S. E., Doshi, D. & Chen, J. D. Prolonged treatment with transcutaneous electrical nerve stimulation (TENS) modulates neuro-gastric motility and plasma levels of vasoactive intestinal peptide (VIP), motilin and interleukin-6 (IL-6) in systemic sclerosis. Clin. Exp. Rheumatol. 31, 140\u2013150 (2013).","journal-title":"Clin. Exp. Rheumatol."},{"key":"900_CR177","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.14309\/ajg.0000000000001203","volume":"116","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. Integrative effects and vagal mechanisms of transcutaneous electrical acustimulation on gastroesophageal motility in patients with gastroesophageal reflux disease. Am. J. Gastroenterol. 116, 1495\u20131505 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR178","doi-asserted-by":"crossref","first-page":"G293","DOI":"10.1152\/ajpgi.00049.2018","volume":"315","author":"Z Liu","year":"2018","unstructured":"Liu, Z. et al. Preventive effects of transcutaneous electrical acustimulation on ischemic stroke-induced constipation mediated via the autonomic pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 315, G293\u2013G301 (2018).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"900_CR179","doi-asserted-by":"crossref","first-page":"762546","DOI":"10.1155\/2015\/762546","volume":"2015","author":"RH Parrado","year":"2015","unstructured":"Parrado, R. H., Lemus, H. N., Coral-Alvarado, P. X. & Quintana L\u00f3pez, G. Gastric antral vascular ectasia in systemic sclerosis: current concepts. Int. J. Rheumatol. 2015, 762546 (2015).","journal-title":"Int. J. Rheumatol."},{"key":"900_CR180","volume":"11","author":"AM Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold, A. M. et al. Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial. BMJ Open. 11, e048541 (2021).","journal-title":"BMJ Open."},{"key":"900_CR181","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","volume":"55","author":"J Raja","year":"2016","unstructured":"Raja, J., Nihtyanova, S. I., Murray, C. D., Denton, C. P. & Ong, V. H. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology 55, 115\u2013119 (2016).","journal-title":"Rheumatology"},{"key":"900_CR182","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/2397198319891282","volume":"6","author":"AM Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold, A. M. & Volkmann, E. R. Gastrointestinal involvement in systemic sclerosis: effects on morbidity and mortality and new therapeutic approaches. J. Scleroderma Relat. Disord. 6, 37\u201343 (2021).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"900_CR183","first-page":"S168","volume":"33","author":"KE Clark","year":"2015","unstructured":"Clark, K. E., Etomi, O., Denton, C. P., Ong, V. H. & Murray, C. D. Intravenous immunoglobulin therapy for severe gastrointestinal involvement in systemic sclerosis. Clin. Exp. Rheumatol. 33, S168\u2013S170 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"900_CR184","doi-asserted-by":"crossref","first-page":"G1052","DOI":"10.1152\/ajpgi.00034.2016","volume":"310","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. Am. J. Physiol. Gastrointest. Liver Physiol. 310, G1052\u2013G1060 (2016).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"900_CR185","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.5152\/eurjrheum.2019.19103","volume":"7","author":"ER Volkmann","year":"2020","unstructured":"Volkmann, E. R. & Hoffmann-Vold, A. M. Gastrointestinal tract microbiota modifications in systemic sclerosis. Eur. J. Rheumatol. 7, S228\u2013S236 (2020).","journal-title":"Eur. J. Rheumatol."},{"key":"900_CR186","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232739","volume":"15","author":"H Fretheim","year":"2020","unstructured":"Fretheim, H. et al. Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial. PLoS One 15, e0232739 (2020).","journal-title":"PLoS One"},{"key":"900_CR187","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/gutjnl-2020-322630","volume":"70","author":"P de Groot","year":"2021","unstructured":"de Groot, P. et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial. Gut 70, 92\u2013105 (2021).","journal-title":"Gut"},{"key":"900_CR188","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.chom.2018.01.003","volume":"23","author":"CS Smillie","year":"2018","unstructured":"Smillie, C. S. et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe 23, 229\u2013240.e225 (2018).","journal-title":"Cell Host Microbe"},{"key":"900_CR189","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1053\/j.gastro.2020.08.045","volume":"159","author":"L Kong","year":"2020","unstructured":"Kong, L. et al. Linking strain engraftment in fecal microbiota transplantation with maintenance of remission in Crohn\u2019s disease. Gastroenterology 159, 2193\u20132202.e2195 (2020).","journal-title":"Gastroenterology"},{"key":"900_CR190","doi-asserted-by":"crossref","first-page":"12672","DOI":"10.1073\/pnas.1904099116","volume":"116","author":"MT Henke","year":"2019","unstructured":"Henke, M. T. et al. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn\u2019s disease, produces an inflammatory polysaccharide. Proc. Natl Acad. Sci. USA 116, 12672\u201312677 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"900_CR191","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2007595118","volume":"118","author":"MT Henke","year":"2021","unstructured":"Henke, M. T. et al. Capsular polysaccharide correlates with immune response to the human gut microbe. Proc. Natl Acad. Sci. USA 118, e2007595118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"900_CR192","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1053\/j.gastro.2020.09.032","volume":"160","author":"AA May-Zhang","year":"2021","unstructured":"May-Zhang, A. A. et al. Combinatorial transcriptional profiling of mouse and human enteric neurons identifies shared and disparate subtypes in situ. Gastroenterology 160, 755\u2013770.e26\u00a0(2021).","journal-title":"Gastroenterology"},{"key":"900_CR193","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cell.2019.12.016","volume":"180","author":"A Jarret","year":"2020","unstructured":"Jarret, A. et al. Enteric nervous system-derived IL-18 orchestrates mucosal barrier immunity. Cell 180, 50\u201363.e12 (2020).","journal-title":"Cell"},{"key":"900_CR194","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1242\/dev.127.14.3045","volume":"127","author":"CV Baker","year":"2000","unstructured":"Baker, C. V. & Bronner-Fraser, M. Establishing neuronal identity in vertebrate neurogenic placodes. Development 127, 3045\u20133056 (2000).","journal-title":"Development"},{"key":"900_CR195","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73777","volume":"11","author":"N Barki","year":"2022","unstructured":"Barki, N. et al. Chemogenetics defines a short-chain fatty acid receptor gut\u2013brain axis. Elife 11, e73777 (2022).","journal-title":"Elife"},{"key":"900_CR196","doi-asserted-by":"crossref","first-page":"G718","DOI":"10.1152\/ajpgi.00293.2020","volume":"319","author":"N Abdullah","year":"2020","unstructured":"Abdullah, N., Defaye, M. & Altier, C. Neural control of gut homeostasis. Am. J. Physiol. Gastrointest. Liver Physiol. 319, G718\u2013G732 (2020).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"900_CR197","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrgastro.2013.29","volume":"10","author":"SJ Brookes","year":"2013","unstructured":"Brookes, S. J., Spencer, N. J., Costa, M. & Zagorodnyuk, V. P. Extrinsic primary afferent signalling in the gut. Nat. Rev. Gastroenterol. Hepatol. 10, 286\u2013296 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"900_CR198","doi-asserted-by":"crossref","first-page":"102811","DOI":"10.1016\/j.autneu.2021.102811","volume":"233","author":"HK Serlin","year":"2021","unstructured":"Serlin, H. K. & Fox, E. A. Neurotrophin-4 is essential for survival of the majority of vagal afferents to the mucosa of the small intestine, but not the stomach. Auton. Neurosci. 233, 102811 (2021).","journal-title":"Auton. Neurosci."},{"key":"900_CR199","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/nyas.14138","volume":"1454","author":"TL Powley","year":"2019","unstructured":"Powley, T. L. et al. Vagal innervation of the stomach reassessed: brain-gut connectome uses smart terminals. Ann. N. Y. Acad. Sci. 1454, 14\u201330 (2019).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"900_CR200","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/nmo.12825","volume":"28","author":"BN Chen","year":"2016","unstructured":"Chen, B. N., Olsson, C., Sharrad, D. F. & Brookes, S. J. Sensory innervation of the guinea pig colon and rectum compared using retrograde tracing and immunohistochemistry. Neurogastroenterol. Motil. 28, 1306\u20131316 (2016).","journal-title":"Neurogastroenterol. Motil."},{"key":"900_CR201","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1002\/cne.24294","volume":"525","author":"A Kamitakahara","year":"2017","unstructured":"Kamitakahara, A., Wu, H. H. & Levitt, P. Distinct projection targets define subpopulations of mouse brainstem vagal neurons that express the autism-associated MET receptor tyrosine kinase. J. Comp. Neurol. 525, 3787\u20133808 (2017).","journal-title":"J. Comp. Neurol."},{"key":"900_CR202","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1523\/JNEUROSCI.2663-18.2019","volume":"39","author":"S Megat","year":"2019","unstructured":"Megat, S. et al. Differences between dorsal root and trigeminal ganglion nociceptors in mice revealed by translational profiling. J. Neurosci. 39, 6829\u20136847 (2019).","journal-title":"J. Neurosci."},{"key":"900_CR203","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1523\/JNEUROSCI.0309-20.2020","volume":"40","author":"X Niu","year":"2020","unstructured":"Niu, X. et al. Mapping of extrinsic innervation of the gastrointestinal tract in the mouse embryo. J. Neurosci. 40, 6691\u20136708 (2020).","journal-title":"J. Neurosci."},{"key":"900_CR204","doi-asserted-by":"crossref","unstructured":"Gabella, G. in The Rat Nervous System 3rd edn (ed. Paxinos, G.) 77\u2013109 (Academic Press, 2004).","DOI":"10.1016\/B978-012547638-6\/50004-3"},{"key":"900_CR205","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/cphy.c130055","volume":"4","author":"KN Browning","year":"2014","unstructured":"Browning, K. N. & Travagli, R. A. Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions. Compr. Physiol. 4, 1339\u20131368 (2014).","journal-title":"Compr. Physiol."},{"key":"900_CR206","doi-asserted-by":"crossref","unstructured":"Benarroch, E. E. in Encyclopedia of the Neurological Sciences 2nd edn (eds Aminoff, M. J. & Daroff, R. B.) 805\u2013808 (Academic Press, 2014).","DOI":"10.1016\/B978-0-12-385157-4.00508-X"},{"key":"900_CR207","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00004836-198604000-00006","volume":"8","author":"GJ Maddern","year":"1986","unstructured":"Maddern, G. J., Kiroff, G. K., Leppard, P. I. & Jamieson, G. G. Domperidone, metoclopramide, and placebo. All give symptomatic improvement in gastroesophageal reflux. J. Clin. Gastroenterol. 8, 135\u2013140 (1986).","journal-title":"J. Clin. Gastroenterol."},{"key":"900_CR208","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1046\/j.1440-1622.2001.02005.x","volume":"71","author":"E Chrysos","year":"2001","unstructured":"Chrysos, E. et al. Erythromycin enhances oesophageal motility in patients with gastro-oesophageal reflux. Anz. J. Surg. 71, 98\u2013102 (2001).","journal-title":"Anz. J. Surg."},{"key":"900_CR209","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/gut.2003.035279","volume":"54","author":"J Arts","year":"2005","unstructured":"Arts, J., Caenepeel, P., Verbeke, K. & Tack, J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 54, 455\u2013460 (2005).","journal-title":"Gut"},{"key":"900_CR210","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/00006231-199509000-00011","volume":"16","author":"CH Kao","year":"1995","unstructured":"Kao, C. H., Wang, S. J. & Pang, D. Y. Effects of oral erythromycin on upper gastrointestinal motility in patients with non-insulin-dependent diabetes mellitus. Nucl. Med. Commun. 16, 790\u2013793 (1995).","journal-title":"Nucl. Med. Commun."},{"key":"900_CR211","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1442-2050.2011.01275.x","volume":"25","author":"M Di Stefano","year":"2012","unstructured":"Di Stefano, M. et al. Effect of buspirone, a 5-HT1A receptor agonist, on esophageal motility in healthy volunteers. Dis. Esophagus 25, 470\u2013476 (2012).","journal-title":"Dis. Esophagus"},{"key":"900_CR212","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1365-2036.2008.03849.x","volume":"28","author":"L Van Oudenhove","year":"2008","unstructured":"Van Oudenhove, L., Kindt, S., Vos, R., Coulie, B. & Tack, J. Influence of buspirone on gastric sensorimotor function in man. Aliment. Pharmacol. Ther. 28, 1326\u20131333 (2008).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"900_CR213","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/2050640615585688","volume":"3","author":"C Scheerens","year":"2015","unstructured":"Scheerens, C., Tack, J. & Rommel, N. Buspirone, a new drug for the management of patients with ineffective esophageal motility? United European Gastroenterol. J. 3, 261\u2013265 (2015).","journal-title":"United European Gastroenterol. J."},{"key":"900_CR214","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4103\/IJPC.IJPC_17_17","volume":"23","author":"N Kumar","year":"2017","unstructured":"Kumar, N., Barai, S., Gambhir, S. & Rastogi, N. Effect of mirtazapine on gastric emptying in patients with cancer-associated anorexia. Indian. J. Palliat. Care 23, 335\u2013337 (2017).","journal-title":"Indian. J. Palliat. Care"},{"key":"900_CR215","doi-asserted-by":"crossref","DOI":"10.1186\/1752-1947-7-38","volume":"7","author":"JY Gooden","year":"2013","unstructured":"Gooden, J. Y. & Takahashi, P. Y. Mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual: a case report. J. Med. Case Rep. 7, 38 (2013).","journal-title":"J. Med. Case Rep."},{"key":"900_CR216","doi-asserted-by":"publisher","unstructured":"Carbone, F., Vanuytsel, T. & Tack, J. The effect of mirtazapine on gastric accommodation, gastric sensitivity to distention, and nutrient tolerance in healthy subjects. Neurogastroenterol. Motil 29, https:\/\/doi.org\/10.1111\/nmo.13146 (2017).","DOI":"10.1111\/nmo.13146"},{"key":"900_CR217","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jpeds.2006.05.029","volume":"149","author":"TI Omari","year":"2006","unstructured":"Omari, T. I. et al. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J. Pediatr. 149, 468\u2013474 (2006).","journal-title":"J. Pediatr."},{"key":"900_CR218","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1476-5381.1986.tb11145.x","volume":"89","author":"PL Andrews","year":"1986","unstructured":"Andrews, P. L. & Wood, K. L. Systemic baclofen stimulates gastric motility and secretion via a central action in the rat. Br. J. Pharmacol. 89, 461\u2013467 (1986).","journal-title":"Br. J. Pharmacol."},{"key":"900_CR219","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/MCG.0b013e318167b89d","volume":"43","author":"W Blonski","year":"2009","unstructured":"Blonski, W., Vela, M. F., Freeman, J., Sharma, N. & Castell, D. O. The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. J. Clin. Gastroenterol. 43, 253\u2013260 (2009).","journal-title":"J. Clin. Gastroenterol."},{"key":"900_CR220","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00455-020-10243-7","volume":"37","author":"SI Dhar","year":"2022","unstructured":"Dhar, S. I. et al. Effects of pyridostigmine on esophageal and pharyngeal motility in dysphagic patients undergoing high-resolution manometry. Dysphagia 37, 4\u201310 (2022).","journal-title":"Dysphagia"},{"key":"900_CR221","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2006.06.018","volume":"131","author":"SF Pasha","year":"2006","unstructured":"Pasha, S. F., Lunsford, T. N. & Lennon, V. A. Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine. Gastroenterology 131, 1592\u20131596 (2006).","journal-title":"Gastroenterology"},{"key":"900_CR222","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1463-1318.2009.01838.x","volume":"12","author":"CJ O\u2019Dea","year":"2010","unstructured":"O\u2019Dea, C. J., Brookes, J. H. & Wattchow, D. A. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. Colorectal Dis. 12, 540\u2013548 (2010).","journal-title":"Colorectal Dis."},{"key":"900_CR223","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40272-017-0277-6","volume":"20","author":"ML Manini","year":"2018","unstructured":"Manini, M. L., Camilleri, M., Grothe, R. & Di Lorenzo, C. Application of pyridostigmine in pediatric gastrointestinal motility disorders: a case series. Paediatr. Drugs 20, 173\u2013180 (2018).","journal-title":"Paediatr. Drugs"},{"key":"900_CR224","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10286-008-0476-x","volume":"18","author":"AE Bharucha","year":"2008","unstructured":"Bharucha, A. E. et al. Pilot study of pyridostigmine in constipated patients with autonomic neuropathy. Clin. Auton. Res. 18, 194\u2013202 (2008).","journal-title":"Clin. Auton. Res."},{"key":"900_CR225","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1007\/s10620-016-4272-5","volume":"61","author":"R Schey","year":"2016","unstructured":"Schey, R. et al. Domperidone to treat symptoms of gastroparesis: benefits and side effects from a large single-center cohort. Dig. Dis. Sci. 61, 3545\u20133551 (2016).","journal-title":"Dig. Dis. Sci."},{"key":"900_CR226","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/j.1572-0241.2007.01255.x","volume":"102","author":"SC Reddymasu","year":"2007","unstructured":"Reddymasu, S. C., Soykan, I. & McCallum, R. W. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am. J. Gastroenterol. 102, 2036\u20132045 (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"900_CR227","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2147\/PPA.S92550","volume":"10","author":"A Shin","year":"2016","unstructured":"Shin, A. Patient considerations in the management of chronic constipation: focus on prucalopride. Patient Prefer. Adherence 10, 1373\u20131384 (2016).","journal-title":"Patient Prefer. Adherence"},{"key":"900_CR228","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/13543784.2017.1301427","volume":"26","author":"CJ Smart","year":"2017","unstructured":"Smart, C. J. & Malik, K. I. Prucalopride for the treatment of ileus. Expert. Opin. Investig. Drugs 26, 489\u2013493 (2017).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"900_CR229","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2036.2011.04947.x","volume":"35","author":"P Oustamanolakis","year":"2012","unstructured":"Oustamanolakis, P. & Tack, J. Prucalopride for chronic intestinal pseudo-obstruction. Aliment. Pharmacol. Ther. 35, 398\u2013399 (2012).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"900_CR230","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1586\/17474124.2016.1150175","volume":"10","author":"J Langworthy","year":"2016","unstructured":"Langworthy, J., Parkman, H. P. & Schey, R. Emerging strategies for the treatment of gastroparesis. Expert Rev. Gastroenterol. Hepatol. 10, 817\u2013825 (2016).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"900_CR231","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.24730","volume":"61","author":"D Khanna","year":"2009","unstructured":"Khanna, D. et al. Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument. Arthritis Rheum. 61, 1257\u20131263 (2009).","journal-title":"Arthritis Rheum."},{"key":"900_CR232","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/ajg.2014.237","volume":"109","author":"BM Spiegel","year":"2014","unstructured":"Spiegel, B. M. et al. Development of the NIH patient-reported outcomes measurement information system (PROMIS) gastrointestinal symptom scales. Am. J. Gastroenterol. 109, 1804\u20131814 (2014).","journal-title":"Am. J. Gastroenterol."}],"updated-by":[{"DOI":"10.1038\/s41584-023-00929-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000}}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00900-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00900-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00900-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T18:29:25Z","timestamp":1728844165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00900-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":232,"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1038\/s41584-022-00900-6","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41584-023-00929-1","asserted-by":"object"}]},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"assertion":[{"value":"20 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C. declares that she is a consultant for Phathom Pharmaceuticals. R.J.X. declares that he is co-founder of Jnana Therapeutics and Celsius Therapeutics, a board member for Moonlake Immunotherapeutics and on the Scientific Advisory Board for Nestle. P.J.P. declares that he is co-founder of, holds equity in and is a consultant for Neurogastrx. D.K. declares that he has received consulting fees from Acceleron, Actelion, Amgen, Bayer, Boehringer Ingelheim, Chemomab, CSL Behring, Genentech\/Roche, Horizon, Paracrine Cell Therapy, Mitsubishi Tanabe Pharma, Prometheus and Theraly. Z.H.M., S.K. and J.Z.C. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}